P826: FACTOR D INHIBITION WITH ORAL BCX9930 LEADS TO SUSTAINED CONTROL OF HEMOLYSIS AND SYMPTOMS OVER 48 WEEKS IN SUBJECTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA INADEQUATELY CONTROLLED ON C5 INHIBITORS
A. Kulasekararaj,
W. Füreder,
A. McDonald,
J. L. R. Malherbe,
S. Gandhi,
D. Collins,
M. Cornpropst,
S. Dobo,
M. K. Farmer,
D. Kargl,
W. Sheridan,
M. Griffin,
A. Risitano
Affiliations
A. Kulasekararaj
1 Kings College Hospital NHS Foundation Trust, London, United Kingdom
W. Füreder
2 Medical University of Vienna, Vienna, Austria
A. McDonald
3 Netcare Pretoria East Hospital, Moreleta Park
J. L. R. Malherbe
4 University of the Free State, Bloemfontein, South Africa
S. Gandhi
1 Kings College Hospital NHS Foundation Trust, London, United Kingdom
D. Collins
5 BioCryst Pharmaceuticals, Durham, United States of America
M. Cornpropst
5 BioCryst Pharmaceuticals, Durham, United States of America
S. Dobo
5 BioCryst Pharmaceuticals, Durham, United States of America
M. K. Farmer
5 BioCryst Pharmaceuticals, Durham, United States of America
D. Kargl
5 BioCryst Pharmaceuticals, Durham, United States of America
W. Sheridan
5 BioCryst Pharmaceuticals, Durham, United States of America
M. Griffin
6 Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
